



COLORADO

Department of Health Care
Policy & Financing

AGENDA
Pharmaceutics & Therapeutics Committee
Department of Health Care Policy & Financing

Zoom Webinar:

<https://primetherapeutics.zoom.us/j/88612629862?pwd=uoQvY5ftvRWQAlw0JwKP2Ki7aRQTsY.1>

Tuesday, July 9, 2024, 1:00-5:00 P.M.

1. Committee Member Introductions

2. Unfinished Business and General Orders

Approval of minutes from April 9, 2024 P&T meeting
Updates from April 9, 2024 P&T Meeting

3. New Business

Updates from the Prior Authorization Call Center

4. Drug Classes Up for Review

Review of Antipsychotics, Long-Acting Injectables
Review of Androgenic Agents - Topical, Injectable, Oral
Review of Bone Resorption Suppression and Related Agents
Review of Diabetes Management Classes - Insulins Long-Acting
Review of Diabetes Management Classes - Non-Insulin

- DPP-4is, GLP-1 Analogues, SGLT-2is

Review of Growth Hormones
Review of Phosphate Binders

Mass review drug classes:

- Contraceptives - Topical
- Diabetes Management Classes - Insulins - Rapid, Short, Intermediate, Mixtures, Concentrated
- Diabetes Management Classes - Non-Insulins
 - Amylin, Biguanides, Meglitinides, TZDs, Combinations
- Estrogen Agents - Oral/Transdermal, Injectable
- Glucagon, Self-Administered
- Prenatal Vitamins/Minerals
- Antihyperuricemics
- Benign Prostatic Hyperplasia (BPH) Agents
- Overactive Bladder Agents



Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jessica.czechowski@primetherapeutics.com and carbon copy: Greg Miller, PDL & Clinical Strategy Pharmacist, greg.l.miller@state.co.us. Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by July 2nd, 2024 by 5pm MST.

5. Adjourn

Upcoming Meeting Date: October 08, 2024.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](mailto:504/ADA) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

